When the time was right to make a powerful Western biotech welcome in China, Beigene Ltd. was ready when Amgen Inc. came calling. Its massive $2.7 billion cash equity investment in Beigene buys Amgen an oncology footprint in China.
With a $17 million series A fundraiser completed, Pinteon Therapeutics Inc., of Cambridge, Mass., is keeping its eyes on the phase I trial it started in September testing PNT-001, a tau antibody that targets cis-pT231 tau, a toxic epitope that drives neurodegenerative disease.
Two phase II stumbles for startup Cyclerion Therapeutics Inc., an Ironwood Pharmaceuticals Inc. spinout, crushed the stock (NADAQ:CYCN), which closed down a steep 79.5% on Wednesday.
Brian MacDonald's pursuit of an approved hepcidin therapy at Merganser Biotech Inc. didn't quite pan out, but that didn't stop him from taking up Atlas Venture's offer to try it once again on a different tack.
Upbeat top-line data for New York-based Iveric Bio Inc.'s phase IIb trial testing Zimura in dry age-related macular degeneration propelled the company stock (NASDAQ:ISEE) 82.8% upward in Monday's trading, a big success in a company that rebranded itself earlier this year.
Roughly 40 years after Bio-Response launched the first-ever biotech IPO, three companies priced IPOs on Friday, riding a wave of momentum that has put 2019 into second place for the most IPO money raised in a single year. Only 2018's record $10.7 billion is beyond this year's total: 54 global IPOs raising $7.98 billion.
Privately held Pepticom Ltd., of Jerusalem, completed a $5 million series A fundraising, allowing it to use artificial intelligence (AI) in helping research centers, pharma and agriculture companies discover advanced peptide-based drug candidates.
Building on the positive phase II results reported in June 2018 for pamrevlumab to treat pancreatic cancer, the first dose has been administered in Fibrogen Inc.'s phase III study in patients with unresectable locally advanced pancreatic cancer.
Despite Provention Bio Inc.'s phase IIa top-line data showing PRV-6527 in Crohn's disease did not differentiate from placebo, the company's stock was bumped back less than 1% on Tuesday as it continued to ride high after June's massive leap on heartening data about the company's type 1 diabetes trial of teplizumab.
